Capricor Therapeutics is trading 10.32% up now at $7.27 on October 15, 2026, as reports linked the advance to attention around its HOPE-3 open-label-extension data at the World Muscle Society congress. - One report said the deramiocel poster became available to delegates. - Biotech-sector strength may also be supportive; XBI was reported up 2.20% during the session. - Capricor’s latest listed release was October 5, pointing to renewed clinical-data attention rather than a new company announcement today.